A Systematic Review about the Efficacy and Safety of Tripterygium wilfordii Hook.f. Preparations Used for the Management of Rheumatoid Arthritis

Table 1

Trials characteristics.

Study ID

Group

Age (year)

Disease duration; (months)

Outcomes

Diagnostic criteria

Active or not

Duration (week)

Intervention group

Control group

Withdrawal/adverse effects

Patients; N (M/F)

Meditation

Using method

Patients; (M/F)

Meditation

Using method

Cao, 2015

TWPs; CWM

47.81 (10.37); 48.94 (10.51)

59.39 (67.11); 61.80 (65.62)

ACR 20/50/70, DAS28, ESR, CRP, RF, CCP, GP, VAS, DMS,; TJC, SJCHAQ, QLT, SDS, SAS, X ray

ARA 1987

Y

12

139; (17/122)

XFC; LEF PLB

3 tid po; 10 mg qd po

143 (27/116)

LEF; XFC PLB

10 mg qd; 3 tid

Y

Jiang et al., 2015

TWPs; CWM

18–75

-

VAS, DAS28, AOT, SOT

ARA 1987; ACR/EULAR 2009

Y

12

28

KXC

2 tid po

28

LEF

20 mg qd

Y

Jiao et al., 2016

TWPs; PLB

52 (9); 52 (10)

120 (96); 102 (77)

VAS, DAS28, ESR, hs-CRP

ARA 1987

-

8

87 (6/81)

FFLTA

20 g qd ext

87 (14/73)

PLB

20 g qd ext

Y

Li, 2010

TWPs; CWM

-

-

TJC, SJC, DMS, QLT, ESR, CRP

ARA 1987

Y

12

33

LJS; MTX PLB

66 g tid po; 15 mg qw po

33

MTX; LJS PLB

15 mg qw po; 66 g tid po

N

Li et al., 2009

TWPs; CPM

44.6 (13.1); 43.6 (14.5)

68.88 (87.12); 66.48 (87.48)

HAQ, DMS, VAS, TJC, SJC, CRP,; ESR, RF

ARA 1987

-

8

53 (15/38)

STTBW; ZQFTN PLB

4 g bid po; 40 mg tid po

54 (12/42)

ZQFTN; STTBW PLB

40 mg tid po; 4 g bid po

Y

Lv et al., 2014

TWPs; CWM

51.3 (8.3); 51.0 (10.3)

61.9 (81.9); 58.8 (88.7)

PAP, PGADA, PGADA, TJC, SJC, ESR, CRP,; HAQ, SF-36, DAS28

ACR/EULAR 2010

Y

24

69 (13/56)

TWHF pills; MTX

20 mg tid po

69 (10/59)

MTX

7.5–12.5 mg qw po

Y

Meng et al., 2013

TWPs; CWM

38.25 (4.43); 39.33 (3.58)

-

TJC, SJC, SC, VAS, DMS, MGS, 15 mWT

ARA 1987

N

12

50 (11/39)

FFLGTYJ

10 ml tid po with honey

50 (9/41)

MTX; DSSRC

10 mg qw po; 50 mg bid po

Y

Wang, 2004

TWPs; CPM

42.64 (14.52); 41.87 (11.96)

94.44 (28.08); 91.56 (26.28)

DMS, MGS, VAS, SJC, TJC, ESR, CRP, RF, IgG, IgM, IgA

ARA 1987

N

12

6 (3/3)

TWHF pills

10 mg tid po

6 (2/4)

YSJBW

8 g tid po

N

Wang et al., 2013

TWPs; CWM

47.43 (8.75); 43.67 (10.10)

67.10 (54.02); 67.93 (56.95)

TJC, SJC, DMS, ESR, CRP, RF, IgG

ARA 1987

Y

4

30 (3/27)

XFC

3 tid po

30 (2/28)

LEF

10 mg qd po

N

Yang and Zhang, 2007

TWPs; CWM

37.6; 35.8

42; 45.6

DMS, TJC, SJC, MGS, 20 mWT, ESR, CRP, RF, IgG, IgM, IgA

ARA 1987

N

4

60 (18/42)

TWHF pills

20 mg tid po

60 (16/44)

MTX

15 mg qw po

Y

Zhou and Yuan, 2013

TWPs; CWM

37.28; 37.25

78.24; 78

DMS, TJC, SJC, MGS, 20 mWT, ESR, CRP, RF

ARA 1987

N

12

500 (123/377)

LDJ

20 ml tid po

60 (15/45)

DSSRC

50 mg bid po

Y

Note. TWPs: Tripterygiumwilfordii Hook.f. preparations; CWM: conventional western medicine; CPM: Chinese patent medicine; PLB: placebo; N: no; Y: yes; -: not mentioned; XFC: Xin Feng capsules; LEF: Leflunomide; KXC: Kun Xian capsules; FFLTA: Fu Fang Lei Gong Teng topical agent; LJS: Lei Gong Teng Jia Su; MTX: Methotrexate; STTBW: San Teng Tong Bi Wan; ZQFTN: Zheng Qing Feng Tong Ning; TWHF pills: Lei Gong Teng Duo Dai pills; LDJ: Lei Gong Teng Dang Gui wine; YSJBW: Yi Shen Juan Bi Wan; DSSRC: Diclofenac Sodium Sustained Release Capsules; ACR20/50/70: American College of Rheumatology Criteria 20/50/70; DAS28: Disease Activity Score 28; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; CCP: cyclic citrullinated peptide (CCP) antibody; hs-CRP: high-sensitivity CRP; VAS: Visual Analogue Scale; DMS: duration of morning stiffness; TJC: tender joint count; SJC: swollen joint count; MGS: mean grip strength; 15 mWT: 15 m walking time; 20 mWT: 20 m walking time; AOT: analgesic onset time; SOT: swelling onset time; SF-36: short form 36 health questionnaire; HAQ: Health Assessment Questionnaire.